These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 1688244)
1. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama. Petersen DD; Kong AN; Jorge LF; Nebert DW; Arias TD Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244 [TBL] [Abstract][Full Text] [Related]
2. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis. Jorge LF; Arias TD; Griese U; Nebert DW; Eichelbaum M Pharmacogenetics; 1993 Oct; 3(5):231-8. PubMed ID: 7904509 [TBL] [Abstract][Full Text] [Related]
3. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Broly F; Meyer UA Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460 [TBL] [Abstract][Full Text] [Related]
4. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816 [TBL] [Abstract][Full Text] [Related]
5. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380 [TBL] [Abstract][Full Text] [Related]
6. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439 [TBL] [Abstract][Full Text] [Related]
7. Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Jorge LF; Eichelbaum M; Griese EU; Inaba T; Arias TD Pharmacogenetics; 1999 Apr; 9(2):217-28. PubMed ID: 10376769 [TBL] [Abstract][Full Text] [Related]
8. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Evans WE; Relling MV Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245 [TBL] [Abstract][Full Text] [Related]
9. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study. Evans WE; Relling MV Mol Pharmacol; 1990 May; 37(5):639-42. PubMed ID: 1971090 [TBL] [Abstract][Full Text] [Related]
10. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134 [TBL] [Abstract][Full Text] [Related]
11. [Human biodiversity and its effects on the pharmacological variability: CYP2D6 and NAT2 enzymes in Amerind populations of Panama, Colombia and Costa Rica]. Jorge LF; Arias TD Rev Med Panama; 1995 Sep; 20(3):98-107. PubMed ID: 8668827 [TBL] [Abstract][Full Text] [Related]
13. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population. Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247 [TBL] [Abstract][Full Text] [Related]
14. [Biotransformation of sparteine in the Cuna American Indians of Panama]. Arias TD; Jorge L; Lee D; Guerrero de Solís N; Escobar J; Barrantes R; Inaba T Rev Med Panama; 1986 Sep; 11(3):199-209. PubMed ID: 3468564 [No Abstract] [Full Text] [Related]
15. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes. Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167 [TBL] [Abstract][Full Text] [Related]
16. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409 [TBL] [Abstract][Full Text] [Related]
17. An observation on the ethnic uniqueness of the debrisoquine and sparteine antimodes: a study in the Ngawbé Guaymí Amerindians of Panamá. Arias TD; Jorge LF Br J Clin Pharmacol; 1989 Oct; 28(4):493-4. PubMed ID: 2590609 [No Abstract] [Full Text] [Related]
18. Polymorphic drug oxidation in humans. Eichelbaum M Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436 [TBL] [Abstract][Full Text] [Related]
19. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454 [TBL] [Abstract][Full Text] [Related]
20. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Gaedigk A; Blum M; Gaedigk R; Eichelbaum M; Meyer UA Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]